Drug intelligence / Profile preview

BSC 1301

Development stage: Preclinical
Lead developer: BiSiChem
Modality: Small Molecules
Administration: Oral

Overview

BSC 1301 is an orally bioavailable small molecule inhibitor of receptor-interacting serine/threonine-protein kinase 1 (RIPK1). It is designed to be non-brain penetrating and acts by inhibiting RIPK1, a key regulator in cell death and inflammation pathways. The drug is being developed primarily for autoimmune disorders. The originator and developer of BSC 1301 is BiSiChem. As of the latest updates, it remains in early research stages with ongoing patent applications[1][2].

Targets

RIPK1 (Receptor-interacting serine/threonine-protein kinase 1)

Beyond the preview

Go deeper on BSC 1301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BSC 1301.

Explore the full profile